Literature DB >> 1556897

Monocyte tumor necrosis factor production in head and neck squamous cell carcinoma.

O Gallo1, S Pinto, S Boccuzzi, M Dilaghi, E Gallina, M Attanasio, A M Gori, F Martini, R Abbate.   

Abstract

Changes in monocyte and macrophage function have been demonstrated in patients with head and neck squamous cell carcinoma. The purpose of this study was to evaluate tumor necrosis factor (TNF) production by activated monocytes from patients with head and neck squamous cell carcinoma and to evaluate its relation to cancer stage, weight loss, and performance status. Monocytes from patients (n = 10) and controls (n = 10) were isolated from peripheral blood mononuclear cells by plastic adherence and incubated with lipopolysaccharide (10 micrograms/mL). The TNF concentration of supernatants was assayed by TNF alpha-specific immunoassay. The TNF production by monocytes from head and neck squamous cell carcinoma patients was significantly higher (P less than .001) than those of controls. No significant relationship was found to cancer stage, weight loss, and performance status. These findings indicate that, in head and neck squamous cell carcinoma patients, an increased TNF production by activated monocytes takes place which does not correlate with cancer stage, cancer-related weight loss, and performance status.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1556897     DOI: 10.1288/00005537-199204000-00014

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  2 in total

1.  Expression of tumor necrosis factor-alpha and interleukin-6 in oral squamous cell carcinoma.

Authors:  Y Nakano; W Kobayashi; S Sugai; H Kimura; S Yagihashi
Journal:  Jpn J Cancer Res       Date:  1999-08

2.  Interleukin-1 beta and interleukin-6 release by peripheral blood monocytes in head and neck cancer.

Authors:  O Gallo; A M Gori; M Attanasio; F Martini; B Giusti; M Boddi; E Gallina; O Fini; R Abbate
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.